On March 17th, 2018, the new cancer research foundation Forschung hilft! (Research helps!) invited to a charity concert by the German Doctors Orchestra in the grand concert hall of the conservatory of Würzburg University.
The wonderful performance started with Carl Maria von Weber’s overture Master of the Spirits. Conducted by Alexander Mottok, Weber’s music shined brightly. The concert eclipsed with Elisabeth Müller’s stellar performance of Camille Saint-Saëns’ impressionistic violin concerto No. 3. Standing ovations after Robert Schumann’s 3rd symphony were rewarded with a special feature of Alexander Mottok’s own composition. – A fine evening indeed!
The German Doctors’ Orchestra was founded in 1989. Its 150 members are predominantly medical doctors of all disciplines but also pharmacists, nurses and medical students. Many of them have a professional musical education. The orchestra consists exclusively of volunteer musicians and are led by Alexander Mottok, a freelance conductor. For more than ten years, the orchestra’s hallmark has been to perform charity concerts at the highest musical level.
The new foundation Forschung hilft! – Research helps! supports promising research projects and extraordinary achievements of scientists at the University of Würzburg, for example through scholarships. Invigorated by the crowdfunding campaign “Your Immune System Becomes Your Weapon Against Cancer”, Würzburg’s foundation “Hilfe im Kampf gegen Krebs” donated €100,000 to the new foundation when it was founded in mid-December 2017. Since then, Forschung hilft! aims to achieve its goals through donations. The Beilhack lab’s research approach has been selected by this charity to propel immunotherapy for cancer treatment.
From April 12th to 13th, 2018 we are organizing the International Else-Kröner-Conference “Translational Immunology – From Target to Therapy V” at the beautiful historical venue of the Juliusspital in Würzburg, Germany.
The Symposium is organized by the Else-Kröner-fellows of our physician-scientist training program of interdisciplinary translational immunology. Würzburg’s Else-Kröner-fellows are ten selected and associated young physicians from different medical disciplines (cardiology, dermatology, gynecology, hematology, internal medicine, oncology, pathology, urology and pediatrics) who are engaged in a structured translational research training program lead by Prof. Andreas Beilhack and Prof. Jörg Wischhusen. Once a year the fellows organize the conference “Translational Immunology – From Target to Therapy”, where they can present and discuss their work with international guest speakers who are leaders in translational immunology research.
You would like to participate? – Register here!
This week, the Beilhack Lab conducted an intensive training course in immunology for the trainees of our DFG research training group RTG2157 “3D Infect”.
Graduate students of RTG2157 3D Infect at Würzburg University advance and employ 3D human tissue models to investigate host-pathogen interactions. The purpose of these models is to reflect the natural infection site in humans to elucidate the molecular and mechanistic basis for interactions between host and microbes. This week, the Beilhack lab offered an intensive training course in immunology. The course addressed concepts in immunology and immunological methods with an emphasis on multicolor flow cytometry. Katja Ottmüller, Tim Steinfatt and Julia Hartweg provided not only theoretical background to the members of the RTG2157 but also hands-on training in laboratory techniques and in-depth data analysis.
Infectious diseases remain one of the leading causes of death. A clear limitation of studying human pathogens is the lack of relevant infection models. This is particularly true for human pathogens for which no animal reservoir is known. Since simple cell lines, cell culture systems or animals are highly artificial models for human pathogens the members of the DFG research training group RTG2157 3D Infect aims to develop and apply novel human 3D infection models based on engineered human tissues. In a joint project with the group of Prof. Markus Sauer, the Beilhack lab actively participates in this endeavor. The study of host-pathogen interactions is also in the Beilhack lab’s focus in the interdisciplinary DFG research consortium TRR124 FungiNet and in collaborations within the Center for Infectious Diseases (ZINF) at Würzburg University with the new Helmholtz Center for RNA-based Infectious Research in Würzburg.
A new study lead by Prof. Kai Hildner from Erlangen University identifies BATF-expressing T cells as key players in intestinal acute graft-versus-host disease (GvHD).
Alloreactive BATF+ effector memory T cells enhance inflammation by producing GM-CSF and augmenting the infiltration of innate immune cells in the intestinal mucosa. Zeng D, J Clin Invest 2018, © JCI.
Surprisingly, the transcription factor BATF controlled the formation of a distinct IL-7 receptor signaling–responsive GM-CSF+ T cell subset. These newly identified pathologic IL-7RhiGM-CSF+ T cells link IL-7, a cytokine previously mostly associated with T cell reconstitution, to the occurrence of acute GVHD. Furthermore, the study revealed GM-CSF derived from alloreactive T cells as a major driver of systemic and intestinal GvHD. These findings pinpoint the newly identified IL-7R/BATF/GM-CSF axis as a promising therapeutic target to prevent or even treat acute GvHD in patients undergoing allogeneic hematopoietic cell transplantation.
The new research article by Evelyn Ullrich et al. appeared today in the Journal of Clinical Investigation. The work resulted from a collaboration of an interdisciplinary team comprising several members of our newly founded DFG research consortium TR221 GvH-GvL between the partner universities Erlangen, Regensburg and Würzburg.
Commentary by Prof. Defu Zheng on this article in the Journal of Clinical Investigation.
Link to research article:
Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K. (2018). BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. J Clin Invest. 2018 Jan 29. pii: 89242. doi: 10.1172/JCI89242. [Epub ahead of print]
On January 23rd principal investigators gathered for the inaugural meeting of the new DFG TRR221 collaborative research center on the modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation in Regensburg.
Allogeneic hematopoietic cell transplantation is a curative treatment regimen for many patients with leukemia and lymphoma. The new TRR221 consortium connects research teams from the universities of Erlangen, Regensburg and Würzburg to address key challenges of allogeneic hematopoietic cell transplantation. The efficacy of this therapy is mediated by the graft-versus-leukemia (GvL) effect by immune cells of the stem cell donor. However, this desired GvL does not occur to the same degree in all patients to prevent leukemia or lymphoma recurrence after allogeneic hematopoietic cell transplantation. Furthermore, the new forming immune system of the donor can attack healthy organ compartments of the stem cell recipients, an unwanted and often life-threatening immune reaction termed graft-versus-host disease (GvHD). Within the first five years after transplantation, about 60 percent of patients die from GVHD or leukemia.
Our new interdisciplinary research consortium aims to develop innovative immunomodulatory strategies for specifically enhancing the GvL effect and for selective attenuation of GvHD. Our most recent meeting in Regensburg provided the opportunity to elect the board of the consortium, to define the key priorities for the near future, and, importantly, to exchange our most recent research results. A great start for an exciting opportunity to tackle together an unsolved medical problem and to help patients through a concerted research effort.
A new paper in Science Immunology identified a molecule called BMP4 that plays a key role in the thymus’ extraordinary natural ability to recover from damage. Collaborating with scientists from the Memorial Sloan Kettering Hospital in New York City and the Fred Hutchinson Cancer Research Center in Seattle revealed how BMP4 and thymic endothelial cells enable thymus repair.
Thymic endothelial cells proved critical for thymic regeneration via their production of bone morphogenetic protein 4 (BMP4). Upon thymus damage, thymic endothelial cells increased their production of BMP4. Endothelial cell-derived BMP4 fostered development, maintenance, and regeneration of thymic epithelial cells. BMP4’s importance on endogenous tissue regeneration offers a potential clinical approach to enhance T cell immunity. Novel treatment regimens based on these findings may promote immune competence in patients undergoing chemo- and radiation therapy.
The Scientist: Researchers Develop a Technique to Regenerate the Mouse Thymus
Medical Press: How the immune system’s key organ regenerates itself
Wertheimer T, Velardi E, Tsai J, Cooper K, Xiao S, Kloss CC, Ottmüller KJ, Mokhtari Z, Brede C, deRoos P, Kinsella S, Palikuqi B, Ginsberg M, Young LF, Kreines F, Lieberman SR, Lazrak A, Guo P, Malard F, Smith OM, Shono Y, Jenq RR, Hanash AM, Nolan DJ, Butler JM, Beilhack A, Manley NR, Rafii S, Dudakov JA, van den Brink MRM. (2018). Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. Sci Immunol 3:19.
In der Arbeitsgruppe für Experimentelle Stammzelltransplantation der Medizinischen Klinik und Poliklinik II des Universitätsklinikums Würzburg ist eine vorerst für ein Jahr befristete
ab Februar 2018 ganztags zu besetzen. Die Vergütung erfolgt nach TV-L.
Unsere wissenschaftliche Arbeitsgruppe beschäftigt sich mit der Frage, wie unser Immunsystem Krankheitserreger und Krebszellen finden und zerstören kann bzw. warum Immunzellen nach Stammzelltransplantation bestimmte Organe des Empfängers attackieren. Zur Beantwortung dieser Fragestellung führen wir Versuche mit lumineszierenden Mäusen, FACS Analyse, Immunfluoreszenzmikroskopie, Immunhistochemie und molekularbiologische Methoden, wie Klonieren, PCR und Real-time-PCR, durch. Unsere Arbeitsgruppe befindet sich in einem freundlichen, interdisziplinären Laborbereich und wir bieten die Möglichkeit in einer guten Arbeitsatmosphäre an einem sehr spannenden Forschungsprogramm aktiv mitzuwirken.
Gesucht sind engagierte, qualifizierte Bewerberinnen und Bewerber, die sich durch Teamgeist, Konzentrationsfähigkeit und Lernbereitschaft auszeichnen. Tierexperimentelle Kenntnisse sind wünschenswert, aber keine Voraussetzung. Bevorzugt werden motivierte Kanditatinnen und Kanditaten mit organisatorischen Fähigkeiten sowie Computer- und Englischkenntnissen.
Schwerbehinderte Bewerberinnen und Bewerber werden bei im Wesentlichen gleicher Eignung bevorzugt berücksichtigt.
Interessenten/-innen senden ihre elektronischen Bewerbungsunterlagen bis zum 19.01.2018 mit dem Kennwort
Bewerbung: MTA/BTA-Stelle an:
Prof. Dr. Dr. Andreas Beilhack
The DFG approves the new research consortium SFB TRR221, which focusses on harnessing anti-leukemia mechanisms without the risk of adverse immune reactions.
The new DFG consortium focuses on the modulation of transplant-versus-host and transplant-against-leukemia immune reactions.
Allogeneic hematopoietic stem cell transplantation is the only curative treatment option for many patients with leukemia and lymphoma. Their effectiveness is based on the so-called graft-versus-leukemia (GvL) effect: The transplanted immune cells of the donor form a new functional immune system in the patient to fight the tumor cells. However, the effect is not sufficient in all patients to prevent the return of leukemia or lymphoma. Furthermore, there is often an undesirable effect in which the immune cells of the donor attack healthy tissue of the patient, termed graft-versus-host disease (GvHD). Within the first five years after transplant, approximately 60 percent of patients die as a result of GvHD or the return of the disease.
A newly formed research consortium investigates how desired GvL responses can be separated from unwanted GvH reactions. The German Research Foundation (DFG) will fund the new SFB Transregio TRR221 consortium on the “Modulation of transplant-versus-host and transplant-against-leukemia immune reactions after allogeneic hematopoietic stem cell transplantation.” Under the leadership of Prof. Wolfgang Herr, three Bavarian universities – Erlangen, Regensburg and Würzburg will investigate the immunological mechanisms of blood stem cell transplantation. The teams of our consortium will address the central problems and deficits of allogeneic hematopoietic stem cell transplantation. Consequently we aim to develop immunomodulatory strategies for the specific enhancement of the GvL effect and for the selective attenuation of GvHD. This collective gain of knowledge will result in new treatment concepts. These will be tested outside the DFG TRR221 in clinical studies with the aim of reducing the incidence of morbidity and mortality of allogenic blood stem cell transplantation by promoting the highly effective GvL immune response without associated GvHD. The consortium is planned to operate for 12 years. On November 24, 2017, after a thorough two-step evaluation process, the DFG approved funding for an initial phase of four years.
With a generous donation, the married couple Merete and Alexander Knauf of the international building materials company of the same name are stimulating a promising basic research project in the Beilhack lab. Based on an entirely new approach, the project aims to control potential life-threatening immune reactions between a stem cell transplant and the recipient’s body.
From left: Prof. Andreas Beilhack and Musga Qureischi from the Experimental Stem Cell Transplantation Research Laboratory, the patrons Merete and Alexander Knauf, and Prof. Alfred Forchel, President of the University of Würzburg. © Arnika Hansen (Uniklinikum Würzburg).
“My wife and I are regularly involved in projects in which we have the impression that we can really help to advance important improvements in our society with financial support,” says Alexander Knauf, managing partner of the globally active building materials company Knauf from Iphofen near the city of Würzburg. Not least because his wife Merete is a medical doctor herself, this subject area is also in their common funding focus. In search of a suitable project, the patrons recently turned to Prof. Alfred Forchel. The President of the University of Würzburg presented them with a range of current local projects. Among them, the married couple Knauf chose a project of Prof. Beilhack with the aim to develop an entirely new immunotherapy concept. “We are talking here of basic research, but extremely goal-oriented and with high translational potential,” emphasizes the scientist Musga Qureischi, who is actively pursuing this project in the Beilhack lab. According to the young scientist, the new strategy specifically targets improvements in stem cell therapy, but if it succeeds, the principle could well be applied to many autoimmune and inflammatory diseases.
Private donation helps to prove effectiveness
“The generous donation of the couple Knauf helps to skip a typical hurdle in the German research funding landscape,” said University President Forchel, explaining: “For the acquisition of public funds, projects such as this must scientifically prove a high probability of success. But to be able to prove this, considerable resources are required. Private sponsors can help close this gap, as a kind of start-up financing. “
If the project goes well, this proof can be achieved within the next two years, according to Prof. Beilhack.